Waystar to Acquire Iodine for $1.25 Billion
Deal News | Jul 23, 2025 | Advent International
Waystar, a healthcare payment software provider, is set to acquire Iodine Software in a deal valued at $1.25 billion. The acquisition aims to enhance Waystar's platform by integrating Iodine's AI-powered clinical intelligence capabilities, which help reduce administrative errors and prevent revenue leakage in healthcare payments. The transaction, funded by a mix of cash and stock, is expected to close by the end of 2025. Iodine's technology will expand Waystar's total addressable market by over 15% and is anticipated to improve gross margin, EBITDA, revenue growth, and non-GAAP net income per share by 2027. With this acquisition, Waystar aims to enhance AI innovation, streamline healthcare payment processes, and deepen relationships with health systems. Advent International, the largest shareholder of Iodine, will only receive shares in the transaction. The anticipated acquisition underscores Waystar's strategy to drive transformation in healthcare payments through advanced AI solutions.
Sectors
- Healthcare Technology
- Private Equity
- Artificial Intelligence
Geography
- United States – The transaction involves companies headquartered in the United States, with significant operations and client bases in the country.
Industry
- Healthcare Technology – The article discusses Waystar's acquisition of Iodine Software to enhance its healthcare payment platform using AI, a key element in healthcare technology innovation.
- Private Equity – Advent International, a private equity firm, is a major shareholder in the transaction, illustrating the role of private equity in M&A activities within the healthcare technology sector.
- Artificial Intelligence – The integration of Iodine's AI-powered clinical intelligence software underscores the focus on artificial intelligence in transforming healthcare payment processes.
Financials
- $1.25 billion – Total enterprise value of the acquisition of Iodine Software by Waystar.
- 15% – Expected expansion of Waystar's total addressable market as a result of the acquisition.
- $271 million – Estimated Q2 2025 revenue for Waystar, representing approximately 15% year-over-year growth.
- 3.5x – Estimated adjusted net leverage ratio at transaction close for Waystar.
- $15 million – Identified run-rate cost synergies expected within 18-24 months after closing the acquisition.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Waystar | Buyer | Company | Waystar is a provider of healthcare payment software aiming to transform healthcare payments through AI. |
| Iodine Software | Target | Company | Iodine Software offers AI-powered clinical intelligence for healthcare providers to improve documentation and prevent revenue leakage. |
| Advent International | Selling Company | Company | Advent International is a leading global private equity firm and the largest shareholder in Iodine Software. |
| Barclays | Financial Advisor to Waystar | Company | Barclays is serving as the exclusive financial advisor to Waystar in this transaction. |
| Simpson Thacher & Bartlett LLP | Legal Advisor to Waystar | Company | Simpson Thacher & Bartlett LLP is providing legal advisory services to Waystar. |
| J.P. Morgan Securities | Financial Advisor to Iodine Software | Company | J.P. Morgan Securities is the exclusive financial advisor to Iodine Software for this transaction. |
| Weil, Gotshal & Manges LLP | Legal Advisor to Iodine Software | Company | Weil, Gotshal & Manges LLP is providing legal advisory services to Iodine Software. |